Monoclonal and polyclonal antibodies against the HCV envelope proteins.
The potential for developing efficient and efficacious therapies for hepatitis C virus continues to improve. Insight into the molecular processes involved in attachment, entry, and fusion suggests that antibodies could potentially inhibit viral replication at any or all of these stages, and the attachment and entry stages present the best target for antibodies that can attack the virus. Monoclonal and polyclonal antibodies present an important therapeutic option in this area, and this article assesses current investigations of several antibodies.
Mir
Heshaam M
HM
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA.
Birerdinc
Aybike
A
Younossi
Zobair M
ZM
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects* / Q000472:pathogenicity; D006526:Hepatitis C / Q000188:drug therapy*; D018937:Hepatitis C Antibodies / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins / Q000494:pharmacology / Q000627:therapeutic use; D008099:Liver / Q000821:virology; D014759:Viral Envelope Proteins / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D018937:Hepatitis C Antibodies; D007136:Immunoglobulins; D014759:Viral Envelope Proteins; C506101:hepatitis C immune globulin, human